NEWTOWN SQUARE, Pa., March 12, 2020 /PRNewswire/ -- Kibow Biotech is pleased to announce that it will mark World Kidney Day, March 12, 2020, with a significant social media campaign to encourage the importance of maintaining kidney function and remembering the kidney transplant shortage that affects patients worldwide. Kibow's dedicated staff will be wearing the official WKD colors and assist End-Stage Renal Patients by painting and scattering transplant rocks (see https://kibowhope.com/world-kidney-day-2020-transplant-rock-painting/) around our office's surrounding areas.
World Kidney Day is a global awareness campaign aimed at raising awareness of the importance of our kidneys
For over 22-years of continuous R&D, Kibow Biotech's team has been privileged to provide support to people worldwide in their struggle with kidney failure, with RENADYL™ (See: www.RENADYL.com). Kibow remains passionate about patient health and continues to focus on helping current patients navigate their kidney care, educating potential patients, and continuing its research efforts on developing new dietary supplement formulations that can provide additional health benefits, specifically, improved quality of life for consumers worldwide.
Kibow's focus has always been delaying the need for dialysis, especially in late-stage CKD III and IV (predialysis) patients with it's patented and proprietary probiotic formulation, Renadyl™. In this regard, Kibow has submitted a proposal on its innovative "Intestinal Dialysis™ Technology" for the KidneyX Phase 2 prize competition and hopes to be a serious contender in this new KidneyX initiative.
Additionally, Kibow has launched a separate pharmaceutical division to transition its kidney health supplement Renadyl to a drug in the Live Biotherapeutic Product (LBP) category. The company has initiated the IND submission process under the Center for Biological Evaluation Research (CBER) and the US FDA regulations and is planning the required clinical trials. This will allow for potential medical reimbursement by private insurers and government health systems like Medicare. Kibow's aim is to make the product more affordable for patients worldwide. This can make a huge impact in possibly reducing the duration of dialysis from four hours to three hours or less and/or reducing its frequency, from three times to two times per week. This could save the US healthcare system between $8.5B and $11.3B in dialysis costs and, more importantly, improve patients' outcomes and raise their Quality of Life (QoL).
About Kibow Biotech, Inc. and Kibow Pharmaceuticals, LLC.: Founded Oct 1, 1997, in Philadelphia, Kibow Biotech specializes in research, development, and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.
The company's extensive scientific (R&D) and clinical data from three different pilot/observational scientific human clinical trials have been published in peer-reviewed scientific /medical journals (http://www.kibowbiotech.com/rd/).
Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA, and the possibility of its approval as a drug in some other countries according to respective governmental authorities.
About Uremic Toxin Reduction Technology – also known as "Intestinal Dialysis™": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.
Kidney health supplement with a pharmaceutical-like validation: Kibow Biotech is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ is not meant to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors. These include but are not limited to the possibility that Renadyl™ may not reduce levels of uremic toxins in each and every individual, due to differences that exist between individuals that cannot be controlled such as genetics and lifestyle factors, as well as environmental factors that would include proper storage of the product and conditions of transport of the product in the chain of commerce. Other factors that could cause or contribute to differences in actual results include, but are not limited to: whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
Director of Business Development & Media Contact:
Mahesh Ranganathan: Director of Business Development; Kibow Biotech, Inc.
(610) 353-5130 or Email: [email protected]
SOURCE Kibow Biotech, Inc.